title: [Protective effect of lipoxin A4 against rhabdomyolysis-induced acute kidney injury in rats].
abstract: OBJECTIVE
  To investigate the protective effect of lipoxin A4 (LXA(4);) against rhabdomyolysis-induced acute kidney injury (AKI) and the possible mechanism.
  
  
  METHODS
  The animal model of AKI was produced by intramuscular injection with glycerol. SD rats were randomly divided into 3 groups: the normal, AKI and LXA(4); groups. Blood urea nitrogen and serum creatinine levels were evaluated using a HITACHI 747 automatic analyzer. For histological examination, sections were stained with HE. The activity of myeloperoxidase (MPO) was detected by spectrophotometer. Expressions of TNF-α, IL-6 were determined by ELISA, and NF-κB in renal tissues was detected by Western blot analysis.
  
  
  RESULTS
  The levels of blood urea nitrogen and serum creatinine decreased, and the injury of kidney was improved significantly in rats treated with LXA(4); as compared with AKI rats (P<0.05). The levels of TNF-α and IL-6, the activity of MPO and the expression of NF-κB were significantly lower in LXA(4); group than in AKI group (P<0.05).
  
  
  CONCLUSIONS
  LXA(4);  can significantly protect rats against AKI partly by blocking NF-κB activation and reducing inflammatory cytokine expression and inflammatory cells infiltration in the kidney.
authors.affiliation: Department of Internal Medicine, Chongqing Changan Hospital, Chongqing, China. denglilideng@163.com
authors.forename: Li-li
authors.initials: LL
authors.lastname: Deng
authors.forename: Ling
authors.initials: L
authors.lastname: Zhong
authors.forename: Jian-rong
authors.initials: JR
authors.lastname: Lei
authors.forename: Lin
authors.initials: L
authors.lastname: Tang
authors.forename: Ling
authors.initials: L
authors.lastname: Liu
authors.forename: Shu-qin
authors.initials: SQ
authors.lastname: Xie
authors.forename: Xiao-hui
authors.initials: XH
authors.lastname: Liao
mesh_terms: D058186:Acute Kidney Injury / Q000517:prevention & control*; D000818:Animals; D015850:Interleukin-6 / Q000096:biosynthesis; D044045:Lipoxins / Q000627:therapeutic use*; D008297:Male; D016328:NF-kappa B / Q000037:antagonists & inhibitors; D009195:Peroxidase / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D012206:Rhabdomyolysis / Q000150:complications*; D014409:Tumor Necrosis Factor-alpha / Q000096:biosynthesis
chemical_list: D015850:Interleukin-6; D044045:Lipoxins; D016328:NF-kappa B; D014409:Tumor Necrosis Factor-alpha; C040527:lipoxin A4; D009195:Peroxidase